Keryx Biopharmaceuticals Financial Statements
Keryx Biopharmaceuticals Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
| Investor Relations | Company Web Site |
This data is provided as per license from EDGAR Online
Keryx Biopharmaceuticals Income Statement
| 2007 | 2006 | 2005 | |
|---|---|---|---|
| Revenue ($ mil.) | 1.0 | 0.5 | 0.6 |
| Gross Profit ($ mil.) | 0.9 | 0.0 | (0.3) |
| Operating Income ($ mil.) | (94.6) | (80.2) | (29.2) |
| Total Net Income ($ mil.) | (90.1) | (73.8) | (26.9) |
| Diluted EPS (Net Income) | (2.07) | (1.76) | (0.78) |
Keryx Biopharmaceuticals Quarterly Statements
| Quarter Ending Mar 08 | Quarter Ending Dec 07 | Quarter Ending Sep 07 | |
|---|---|---|---|
| Revenue ($ mil.) | 0.2 | 0.9 | 0.1 |
| Gross Profit ($ mil.) | -- | 0.9 | 0.0 |
| Operating Income ($ mil.) | (33.3) | (30.1) | (20.5) |
| Total Net Income ($ mil.) | (34.5) | (29.3) | (19.5) |
| Diluted EPS (Net Income) | (0.79) | (0.67) | (0.45) |
Keryx Biopharmaceuticals Stock Quote & Chart
09/05/08 15:00:03 EST •
NASDAQ •
0.48
•
 0.0000
•
0.0000 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
Keryx Biopharmaceuticals Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 14.13 | 3.75 | 1.56 |
| Price/Earnings Ratio | -- | 16.34 | 15.82 |
| Price/Book Ratio | 1.57 | 2.92 | 1.52 |
| Price/Cash Flow Ratio | -- | 13.17 | 9.88 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Keryx Biopharmaceuticals Financial Ratios
Keryx Biopharmaceuticals Competitive Intelligence
| Baxter | Shire | Wyeth Pharmaceuticals | |
|---|---|---|---|
| Annual Sales ($ mil.) | 11,263.0 | -- | 16,884.2 |
| Employees | 46,000 | 103 | 4,500 |
| Market Cap ($ mil.) | 43,566.0 | -- | -- |
Competitive Landscape
